


I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to:

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

On FEBRUARY 19, 2004

TOWNSEND and TOWNSEND and CREW LLP

By: Kimberly Rose



PATENT
Attorney Docket No.: 015280-310100US
Client Reference No.: E-057-97/1

RECEIVED

FEB 27 2004

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

FITZGERALD, David J.

Application No.: 09/462,682

Filed: April 28, 2000

For: *PSEUDOMONAS EXOTOXIN A-LIKE CHIMERIC IMMUNOGENS*

Examiner: Portner, Virginia Allen

Art Unit: 1645

**SUPPLEMENTAL INFORMATION
DISCLOSURE STATEMENT UNDER 37
CFR §1.97 and §1.98**

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

The references cited on attached form PTO/SB/08A and PTO/SB/08B are being called to the attention of the Examiner. Copies of the reference Nos. 1-39 are enclosed. Copy of reference No. 0 is not enclosed, since it is a continuation application of USSN 09/462,713 whose specification has been previously disclosed.

It is respectfully requested that the cited references be expressly considered during the prosecution of this application, and the references be made of record therein and appear among the "references cited" on any patent to issue therefrom.


As provided for by 37 CFR 1.97(g) and (h), no inference should be made that the information and references cited are prior art merely because they are in this statement and no

representation is being made that a search has been conducted or that this statement encompasses all the possible relevant information.

This IDS is being filed before the mailing date of the final Office Action or Notice of Allowance.

Please charge the IDS fee of \$180 to Deposit Account No. 20-1430. Please deduct any additional fees from, or credit any overpayment to, the above-noted Deposit Account.

Respectfully submitted,



Frank J. Mycroft
Reg. No. 46,946

TOWNSEND and TOWNSEND and CREW LLP
Two Embarcadero Center, Eighth Floor
San Francisco, California 94111-3834
Tel: 925-472-5000
Fax: 925-472-8895
FJM:mrv

60141183 v1



| | | | |
|--|---|-----------------------------------|-------------------------|
| Substitute for form 1449A/PTO U.S. PATENT & TRADEMARK OFFICE | | Complete if Known RECEIVED | |
| INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i> | | Application Number | 09/462,682 |
| | | Filing Date | April 28, 2000 |
| | | First Named Inventor | FitzGerald, David |
| | | Art Unit | 1645 |
| | | Examiner Name | Portner, Virginia Allen |
| Sheet | 1 | of | 3 |
| | | Attorney Docket Number | |
| | | 015280-310100US | |

U.S. PATENT DOCUMENTS+

| U.S. PATENT DOCUMENTS | | | | |
|-----------------------|-----------------------|--|------------------|---|
| | | Document Number | | |
| Examiner Initials* | Cite No. ¹ | Number Kind Code ² (if known) | Publication Date | Name of Patentee or Applicant of Cited Document |
| | | | MM-DD-YYYY | |
| | 0 | US-10/659,036 | n/a | Fitzgerald et al. |
| | 1 | US-4,545,985 | 10-08-1985 | Pastan et al. |
| | 2 | US-5,573,916 | 11-12-1996 | Cheronis et al. |
| | 3 | US-5,821,238 | 10-13-1998 | Pastan et al. |
| | 4 | US-5,869,045 | 02-09-1999 | Hellstrom et al. |
| | 5 | US-5,980,896 | 11-09-1999 | Hellstrom et al. |
| | 6 | US-6,011,002 | 01-04-2000 | Pastan et al. |
| | 7 | US-6,020,145 | 02-01-2000 | Hellstrom et al. |
| | 8 | US-6,051,405 | 04-18-2000 | Fitzgerald et al. |
| | 9 | US-6,099,842 | 08-08-2000 | Pastan et al. |
| | 10 | US-6,140,066 | 10-31-2000 | Lorberboum-Galski et al. |
| | 11 | US-6,423,513 B1 | 06-23-2002 | Fitzgerald et al. |
| | 12 | US-6,426,075 B1 | 06-30-2002 | Fitzgerald et al. |
| | 13 | US-6,531,133 B1 | 03-11-2003 | Lorberboum-Galski et al. |

FOREIGN PATENT DOCUMENTS

| | | | |
|-----------------------|--|--------------------|--|
| Examiner Signature | | Date Considered | |
|-----------------------|--|--------------------|--|

¹EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ² Applicant's unique citation designation number (optional). ³ Kind Codes of U.S. Patent Documents at www.uspto.gov or MPEP 901.04. ⁴ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁵ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁶ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

O I P E
FEB 23 2004
PATENT TRADEMARK OFFICE

Substitute for form 1449SB/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet

2

of

3

Complete if Known

RECEIVED

| | |
|----------------------|-------------------------|
| Application Number | 09/462,682 |
| Filing Date | April 28, 2000 |
| First Named Inventor | FitzGerald, David |
| Art Unit | 1645 |
| Examiner Name | Portner, Virginia Allen |

FEB 27 2004

Attorney Docket Number 015280-310100US

NON PATENT LITERATURE DOCUMENTS

| Examiner Initials * | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T ² |
|---------------------|-----------------------|---|----------------|
| | 14 | BATRA, J.K. et al.: "Single-chain immunotoxins directed at the human transferring receptor containing <i>Pseudomonas</i> exotoxin A or diphtheria toxin: anti-TFR(Fv)-PE40 and DT388-anti-TFR(Fv)" <i>Mol. Cell. Biol.</i> ; Vol. 11, No. 4; pp. 2200-2205 (Apr. 1991) | Abstr. only |
| | 15 | BERAUD, E. et al.: "Immunospecific suppression of encephalitogenic-activated T lymphocytes by chimeric cytotoxin IL-2-PE40" <i>Cell. Immunol.</i> ; Vol. 133, No. 2; pp. 379-389 (Apr. 1991) | Abstr. only |
| | 16 | CHOE, M. et al.: "B3(Fab)-PE38M: a recombinant immunotoxin in which a mutant form of <i>Pseudomonas</i> exotoxin is fused to the Fab fragment of monoclonal antibody B3" <i>Cancer Res.</i> ; Vol. 54, No. 13; pp. 3460-3467 (Jul. 1994) | Abstr. only |
| | 17 | DEBINSKI, W. and I. PASTAN: "Recombinant F(ab') C242- <i>Pseudomonas</i> exotoxin, but not the whole antibody-based immunotoxin, causes regression of a colorectal tumor xenograft" <i>Clin. Cancer Res.</i> ; Vol. 1; pp. 1015-1022 (Sept. 1995) | |
| | 18 | GAWLAK, S.L. et al.: "Basic fibroblast growth factor- <i>Pseudomonas</i> exotoxin chimeric proteins: comparison with acidic fibroblast growth factor- <i>Pseudomonas</i> exotoxin" <i>Bioconjug. Chem.</i> ; Vol. 4, No. 6; pp. 483-489 | Abstr. only |
| | 19 | GORSE, G.J. et al.: "Salivari binding antibodies induced by human immunodeficiency virus type 1 recombinant gp120 vaccine" <i>Clinical and Diagnostic Laboratory Immunology</i> ; Vol. 3, No. 6; pp. 769-773 (1996) | |
| | 20 | HELMBROOK, D.C. et al.: "Transforming growth factor alpha- <i>Pseudomonas</i> exotoxin fusion protein prolongs survival of nude mice bearing tumor xenografts" <i>Proc. Natl. Acad. Sci. USA</i> ; Vol. 87, No. 12; pp. 4697-4701 (Jun. 1990) | Abstr. only |
| | 21 | JOHANSEN, H. K. "Potential of preventing <i>Pseudomonas aeruginosa</i> lung infections in cystic fibrosis patients: experimental studies in animals" <i>APMIS Suppl.</i> ; No. 63, Vol. 104; pp. 5-42 (1996) | |
| | 22 | JOHANSEN, H. K. et al.: "Clearance of <i>Pseudomonas aeruginosa</i> from normal rat lungs after immunization with somatic antigens or toxin A" <i>APMIS</i> ; No. 102; pp. 545-553 (1994) | |
| | 23 | KREITMAN, R.J. et al.: "Properties of chimeric toxins with two recognition domains: interleukin 6 and transforming growth factor alpha at different locations in <i>Pseudomonas</i> exotoxin" <i>Bioconjug. Chem.</i> ; Vol. 3, No. 1; pp. 63-68 | Abstr. only |
| | 24 | KREITMAN, R.J. and I. PASTAN: "Purification and characterization of IL6-PE4E, a recombinant fusion of interleukin 6 with <i>Pseudomonas</i> exotoxin" <i>Bioconjug. Chem.</i> ; Vol. 4, No. 6; pp. 581-585 | Abstr. only |
| | 25 | KUAN, C.T. and I. PASTAN: "Improved antitumor activity of a recombinant anti-Lewis immunotoxin not requiring proteolytic activation" <i>Proc. Natl. Acad. Sci. USA</i> ; Vol. 93; pp. 974-978 (Feb. 1996) | |
| | 26 | KUAN, C.T. et al.: "Immunotoxins containing <i>Pseudomonas</i> exotoxin that target LeY damage human endothelial cells in an antibody-specific mode: relevance to vascular leak syndrome" <i>Clin. Cancer Res.</i> ; Vol. 1, No. 12; pp. 1589-1594 (Dec. 1995) | Abstr. only |
| | 27 | KUAN, C.T. et al.: " <i>Pseudomonas</i> exotoxin A mutans. Replacement of surface exposed residues in domain II with cysteine residues that can be modified with polyethylene glycol in a site-specific manner" <i>J. Biol. Chem.</i> ; Vol. 269, No. 10; pp. 7610-7616 (Mar. 1994) | Abstr. only |
| | 28 | LEGER, O.J.P. et al.: "Humanization of a mouse antibody against alpha-4 integrin: a potential therapeutic for the treatment of multiple sclerosis" <i>Human Antibodies</i> ; Vol. 8; No. 1; pp. 3-16 (1997) | |
| | 29 | MANSFIELD, E. et al.: "Characterization of RFB4- <i>Pseudomonas</i> exotoxin A immunotoxins targeted to CD22 on B-cell malignancies" <i>Bioconjug. Chem.</i> ; Vol. 7, No. 5; pp. 557-563 | Abstr. only |

| | |
|--------------------|-----------------|
| Examiner Signature | Date Considered |
|--------------------|-----------------|

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

RECEIVED

FEB 23 2004

Substitute for Form 1449B/PTO

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet

3

of

3

Complete if Known

| | |
|----------------------|-------------------------|
| Application Number | 09/462,682 |
| Filing Date | April 28, 2000 |
| First Named Inventor | FitzGerald, David |
| Art Unit | 1645 |
| Examiner Name | Portner, Virginia Allen |

| | | | | | |
|-------|---|----|---|------------------------|-----------------|
| Sheet | 3 | of | 3 | Attorney Docket Number | 015280-310100US |
|-------|---|----|---|------------------------|-----------------|

NON PATENT LITERATURE DOCUMENTS

| Examiner Initials * | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T ² |
|---------------------|-----------------------|--|----------------|
| | 30 | MICKISCH, G.H. et al.: "Pseudomonas exotoxin conjugated to monoclonal antibody MRK16 specifically kills multidrug resistant cells in cultured renal carcinomas and in MDR-trasgenic mouse" <i>J. Urol.</i> ; Vol. 149, No. 1; pp. 174-178 (Jan. 1993) | Abstr. only |
| | 31 | PAI, L.H. et al.: "Antitumor activity of a transforming growth factor alpha-Pseudomonas exotoxin fusion protein (TGF-alpha-PE40)" <i>Cancer Res.</i> ; Vol. 51, No. 11; pp. 2808-2812 (Jun. 1991) | Abstr. only |
| | 32 | PAI, L.H. et al.: "Treatment of advanced solid tumors with immunotoxin LMB-1: an antibody linked to Pseudomonas exotoxin" <i>Nat. Med.</i> ; Vol. 2, No. 3; pp. 350-353 (Mar. 1996) | Abstr. only |
| | 33 | PARR, E.L. and M. B. PARR: "Immunoglobulin G is the main protective antibody in mouse vaginal secretions after vaginal immunization with attenuated HSV-2." <i>J. Virol.</i> ; pp. 8109-8115 (1997) | |
| | 34 | PURI, R.K. et al.: "A chimeric protein comprised of IL-4 and Pseudomonas exotoxin is cytotoxic for activated human lymphocytes" <i>J. Immunol.</i> ; Vol. 152, No. 7; pp. 3693-3700 (Apr. 1994) | Abstr. only |
| | 35 | REITER, Y et al.: "Cytotoxic and antitumor activity of a recombinant immunotoxin composed of disulfide-stabilized anti-Tac Fv fragment and truncated Pseudomonas exotoxin" <i>Int. J. Cancer</i> ; Vol. 58, No. 1; pp. 142-149 (Jul. 1994) | Abstr. only |
| | 36 | SIEGALL, C.B. et al.: "In vivo activities of acidic fibroblast growth factor-Pseudomonas exotoxin fusion proteins" <i>Bioconjug. Chem.</i> ; Vol. 5, No. 1; pp. 77-83 | Abstr. only |
| | 37 | THEUER, C. et al.: "Domain II of Pseudomonas exotoxin A arrests the transfer of translocating nascent chains into mammalian microsomes" <i>Biochemistry</i> ; Vol. 33, No. 19; pp. 5894-5900 (May 1994) | Abstr. only |
| | 38 | THEUER, C.P. et al.: "Immunotoxins made with a recombinant form of Pseudomonas exotoxin A that do not require proteolysis for activity" <i>Cancer Res.</i> ; Vol. 53, No. 2; pp. 340-347 (Jan. 1993) | Abstr. only |
| | 39 | THEUER, C.P. et al.: "The N-terminal region of the 37-kDa translocated fragment of Pseudomonas exotoxin A aborts translocation by promoting its own export after microsomal membrane insertion" <i>Proc. Acad. Natl. Sci. USA</i> ; Vol. 90, No. 16; pp. 7774-7778 (Aug. 1993) | Abstr. only |

| | |
|--------------------|-----------------|
| Examiner Signature | Date Considered |
|--------------------|-----------------|

¹EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

²Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.